287 related articles for article (PubMed ID: 8932544)
1. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma.
Northfelt DW; Martin FJ; Working P; Volberding PA; Russell J; Newman M; Amantea MA; Kaplan LD
J Clin Pharmacol; 1996 Jan; 36(1):55-63. PubMed ID: 8932544
[TBL] [Abstract][Full Text] [Related]
2. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma.
Coukell AJ; Spencer CM
Drugs; 1997 Mar; 53(3):520-38. PubMed ID: 9074848
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma.
Amantea MA; Forrest A; Northfelt DW; Mamelok R
Clin Pharmacol Ther; 1997 Mar; 61(3):301-11. PubMed ID: 9084455
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy.
Northfelt DW; Dezube BJ; Thommes JA; Levine R; Von Roenn JH; Dosik GM; Rios A; Krown SE; DuMond C; Mamelok RD
J Clin Oncol; 1997 Feb; 15(2):653-9. PubMed ID: 9053490
[TBL] [Abstract][Full Text] [Related]
5. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.
Northfelt DW; Dezube BJ; Thommes JA; Miller BJ; Fischl MA; Friedman-Kien A; Kaplan LD; Du Mond C; Mamelok RD; Henry DH
J Clin Oncol; 1998 Jul; 16(7):2445-51. PubMed ID: 9667262
[TBL] [Abstract][Full Text] [Related]
6. Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma.
Sharpe M; Easthope SE; Keating GM; Lamb HM
Drugs; 2002; 62(14):2089-126. PubMed ID: 12269857
[TBL] [Abstract][Full Text] [Related]
7. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.
Gabizon A; Martin F
Drugs; 1997; 54 Suppl 4():15-21. PubMed ID: 9361957
[TBL] [Abstract][Full Text] [Related]
8. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin.
Berry G; Billingham M; Alderman E; Richardson P; Torti F; Lum B; Patek A; Martin FJ
Ann Oncol; 1998 Jul; 9(7):711-6. PubMed ID: 9739435
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma.
Cooley T; Henry D; Tonda M; Sun S; O'Connell M; Rackoff W
Oncologist; 2007 Jan; 12(1):114-23. PubMed ID: 17227906
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group.
Goebel FD; Goldstein D; Goos M; Jablonowski H; Stewart JS
Br J Cancer; 1996 Apr; 73(8):989-94. PubMed ID: 8611437
[TBL] [Abstract][Full Text] [Related]
11. Combined delivery and magnetic resonance imaging of neural cell adhesion molecule-targeted doxorubicin-containing liposomes in experimentally induced Kaposi's sarcoma.
Grange C; Geninatti-Crich S; Esposito G; Alberti D; Tei L; Bussolati B; Aime S; Camussi G
Cancer Res; 2010 Mar; 70(6):2180-90. PubMed ID: 20215497
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.
Gill PS; Wernz J; Scadden DT; Cohen P; Mukwaya GM; von Roenn JH; Jacobs M; Kempin S; Silverberg I; Gonzales G; Rarick MU; Myers AM; Shepherd F; Sawka C; Pike MC; Ross ME
J Clin Oncol; 1996 Aug; 14(8):2353-64. PubMed ID: 8708728
[TBL] [Abstract][Full Text] [Related]
13. Liposomal doxorubicin in AIDS-related Kaposi's sarcoma: long-term experiences.
Wagner D; Kern WV; Kern P
Clin Investig; 1994 Jun; 72(6):417-23. PubMed ID: 7950152
[TBL] [Abstract][Full Text] [Related]
14. AIDS-related Kaposi's sarcoma: a phase II study of liposomal doxorubicin. The TLC D-99 Study Group.
Cheung TW; Remick SC; Azarnia N; Proper JA; Barrueco JR; Dezube BJ
Clin Cancer Res; 1999 Nov; 5(11):3432-7. PubMed ID: 10589755
[TBL] [Abstract][Full Text] [Related]
15. FDA approves KS drug. Food and Drug Administration. Florida Department of Health and Rehabilitation Services.
AIDS Alert; 1996 Jan; 11(1):11-2. PubMed ID: 11363227
[TBL] [Abstract][Full Text] [Related]
16. Development of liposomal anthracyclines: from basics to clinical applications.
Gabizon A; Goren D; Cohen R; Barenholz Y
J Control Release; 1998 Apr; 53(1-3):275-9. PubMed ID: 9741935
[TBL] [Abstract][Full Text] [Related]
17. Psoriasiform pustular eruptions from pegylated-liposomal doxorubicin in AIDS-related Kaposi's sarcoma.
Kreuter A; Gambichler T; Schlottmann R; Altmeyer P; Brockmeyer N
Acta Derm Venereol; 2001; 81(3):224. PubMed ID: 11558892
[No Abstract] [Full Text] [Related]
18. Liposomal doxorubicin for treatment of AIDS-related Kaposi's sarcoma.
Simpson JK; Miller RF; Spittle MF
Clin Oncol (R Coll Radiol); 1993; 5(6):372-4. PubMed ID: 8305358
[TBL] [Abstract][Full Text] [Related]
19. Liposomal doxorubicin: new preparation. Useful in Kaposi's sarcoma.
Prescrire Int; 1998 Jun; 7(35):69-70. PubMed ID: 10342919
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma.
Fumagalli L; Zucchetti M; Parisi I; Viganò MG; Zecca B; Careddu A; D'Incalci M; Lazzarin A
Cancer Chemother Pharmacol; 2000; 45(6):495-501. PubMed ID: 10854138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
